October 19, 2016 / 11:20 AM / 9 months ago

Merck's antiviral drug meets main goal in late-stage trial

1 Min Read

Oct 19 (Reuters) - Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.

Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients. (Reporting by Shailesh Kuber; Editing by Martina D'Couto)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below